Literature DB >> 3724180

Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis.

H Ekberg, K G Tranberg, C Lundstedt, G Hanff, J Ranstam, B Jeppsson, S Bengmark.   

Abstract

A consecutive series of 73 patients treated with intraarterial infusion of 5-fluorouracil (5-FU) for liver metastases from colorectal primary was studied retrospectively using multivariate analysis in order to find determinants of survival. Nontreatment factors had a great impact on variation in survival with liver tumor volume and metastases to lymph glands in the liver hilum as major prognostic determinants. In addition, survival from onset of treatment varied with the interval between the primary operation and the diagnosis of liver metastases. Treatment with intraarterial 5-FU was more effective when administered at long-term (3 months every 6 months) than at short-term (5 days every 6 weeks). Single temporary dearterialization, used as an adjunct to infusion of 5-FU, had a negative impact on length of survival and was followed by a high frequency of complications. The occurrence of hepatic arterial thrombosis was associated with comparatively good prognosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3724180     DOI: 10.1002/jso.2930310406

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

Review 1.  Resection of liver metastases from a colorectal carcinoma does not benefit the patient.

Authors:  T M Hunt; N Carty; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1990-05       Impact factor: 1.891

2.  The prevention of arterial collaterals after repeated temporary blockade of the hepatic artery in pigs.

Authors:  B G Persson; B Jeppsson; L Andersson; S E Strand; L Ekelund; S Bengmark
Journal:  World J Surg       Date:  1987-10       Impact factor: 3.352

3.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity.

Authors:  Y Maehara; Y Sakaguchi; Y Emi; T Kusumoto; S Kohnoe; M Mori; K Sugimachi
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

5.  A comparison of methods to measure the percentage hepatic replacement with colorectal metastases.

Authors:  T M Hunt; A D Flowerdew; I Taylor; D M Ackery; R M Blaquiere; K Dewbury
Journal:  Ann R Coll Surg Engl       Date:  1989-01       Impact factor: 1.891

6.  Liver regional continuous chemotherapy: use of femoral or subclavian artery for percutaneous implantation of catheter-port systems.

Authors:  An-Long Zhu; Lian-Xin Liu; Da-Xun Piao; Ya-Xin Lin; Jin-Peng Zhao; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

7.  An association between parameters of liver blood flow and percentage hepatic replacement with tumour.

Authors:  T M Hunt; A D Flowerdew; A J Britten; J S Fleming; S J Karran; I Taylor
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.